Intra-Cellular Therapies Inc.
June 18, 2024 - by Joey Ramson
$ITCI is leading the Prism MarketView Psychedelics index today after the company said a Phase 3 trial of its depression treatment met its primary and secondary endpoints. The trial drug lumateperone, is being developed for use in the treatment of major depressive disorders.
